Photo Credit: CarrieCaptured

The following is a summary of “Real-world satisfaction and experience with injection and autoinjector device for ofatumumab indicated for multiple sclerosis,” published in the January 2025 issue of Neurology by Ross et al.

Researchers conducted a retrospective study to evaluate the satisfaction, device usability, and injection experience of patients with multiple sclerosis (MS) self-administering ofatumumab using the Sensoready® autoinjector in the US.

They conducted a US-based, cross-sectional survey of patients with MS (≥18 years) who self-administered ofatumumab using the Sensoready device within the past 12 months. Eligible patients completed a 30-item questionnaire assessing device satisfaction, usability, convenience, user confidence, injection experience, and administration time, with ratings on Likert and numeric scales. Higher scores indicated positive responses. 

The results showed that 105 patients with MS (65 disease-modifying therapy (DMT)-experienced, 40 DMT-naïve) participated, with a mean age of 42.5 (standard deviation [SD]12.2) years. The overall satisfaction with the Sensoready device was high, with 86.7% rating 4 or 5 on a 5-point Likert scale. The mean satisfaction score was 4.4 (SD 0.7), higher in the DMT-experienced group (4.6 [SD 0.66]) compared to the DMT-naïve group (4.1 [SD 0.69]). Patients who experienced DMT reported higher satisfaction (90.8% vs 80.0%). Key satisfaction factors included administration time (90.5%), ease of use (89.5%), monthly dosing (89.5%), and device preparation time (86.7%). Most patients felt confident using the device, and 77.1% reported no interference with daily activities, with more DMT-experienced patients reporting no interference (83.1% vs 67.5%). 

Investigators found high satisfaction and positive experiences with the Sensoready device in patients with MS, driven by ease of use and reasonable administration time. 

Source: bmcneurol.biomedcentral.com/articles/10.1186/s12883-024-04007-1